#BEGIN_DRUGCARD DB00698

# AHFS_Codes:
08:36.00

# ATC_Codes:
J01XE01

# Absorption:
Readily absorbed in GI tract primarily in small intestine. Enhanced by food or delayed gastric emptying via enhanced dissolution rate of the drug.

# Biotransformation:
Partially metabolized in liver to aminofurantoin.

# Brand_Mixtures:
Not Available

# Brand_Names:
Alfuran
Apo-Nitrofurantoin
Benkfuran
Berkfurin
Ceduran
Chemiofuran
Cistofuran
Cyantin
Cystit
Dantafur
Fua Med
Fuamed
Fur-Ren
Furabid
Furachel
Furadantin
Furadantin Retard
Furadantina MC
Furadantine
Furadantine Mc
Furadantine-Mc
Furadantoin
Furadoin
Furadoine
Furadonin
Furadonine
Furadontin
Furalan
Furaloid
Furan
Furanite
Furantoin
Furantoina
Furatoin
Furedan
Furina
Furobactina
Furophen T
Furophen T-Caps
Gerofuran
It-Uran
Ituran
Ivadantin
Macpac
Macrobid
Macrodantin
Macrodantina
Macrofuran
Macrofurin
N-Toin
Nierofu
Nifurantin
Nitoin
Nitrex
Nitrofan
Nitrofur-C
Nitrofuradantin
Novo-Furantoin
Novofuran
Orafuran
Parfuran
Phenurin
Ro-Antoin
Siraliden
Trantoin
USAF EA-2
Uerineks
Upiol
Urantoin
Urizept
Uro-Selz
Uro-Tablinen
Urodin
Urofuran
Urofurin
Urolisa
Urolong
Uvaleral
Welfurin
Zoofurin

# CAS_Registry_Number:
67-20-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H6N4O5

# Chemical_IUPAC_Name:
1-[(Z)-[(5-nitrofuran-2-yl)methylidene]amino]imidazolidine-2,4-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
319511

# Description:
A bacteriostatic or bactericidal agent depending on the concentration and susceptibility of the infecting organism. Nitrofurantoin is active against some gram positive organisms such as S. aureus, S. epidermidis, S. saprophyticus, Enterococcus faecalis, S. agalactiae, group D streptococci, viridians streptococci and Corynebacterium. Its spectrum of activity against gram negative organisms includes E. coli, Enterobacter, Neisseria, Salmonella and Shigella. It may be used as an alternative to trimethoprim/sulfamethoxazole for treating urinary tract infections though it may be less effective at eradicating vaginal bacteria. May also be used in females as prophylaxis against recurrent cystitis related to coitus. Nitrofurantoin is highly stable to the development of bacterial resistance, a property thought to be due to its multiplicity of mechanisms of action.

# Dosage_Forms:
Capsule	Oral
Tablet	Oral

# Drug_Category:
Anti-Infective Agents, Urinary
Anti-Infectives

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.47

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
79.5 mg/L (at 24 °C)

# Food_Interactions:
Do not take magnesium at the same time.
Take with food since it increases bioavailability and reduces irritation.

# GenBank_ID:
Not Available

# Generic_Name:
Nitrofurantoin

# HET_ID:
Not Available

# Half_Life:
0.3-1 hour

# InChI_Identifier:
InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3-

# InChI_Key:
InChIKey=NXFQHRVNIOXGAQ-OQFOIZHKSA-N

# Indication:
May be used as an alternative in the treatment of urinary tract infections. May be used by females pericoitally for prophylaxis against recurrent cystitis related to coitus.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00439

# LIMS_Drug_ID:
698

# Mechanism_Of_Action:
Nitrofurantoin is activated by bacterial flavoproteins (nitrofuran reductase) to active reduced reactive intermediates that are thought to modulate and damage ribosomal proteins or other macromolecules, especially DNA, causing inhibition of DNA, RNA, protein, and cell wall synthesis. The overall effect is inhibition of bacterial growth or cell death.

# Melting_Point:
263 °C

# Molecular_Weight_Avg:
238.157

# Molecular_Weight_Mono:
238.033819322

# Organisms_Affected:
Gram negative and gram positive bacteria

# PDB_Experimental_ID:
1P87

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450640

# Pharmacology:
Nitrofurantoin exhibits bacteriostatic or bactericidal effects by inhibiting the synthesis of DNA, RNA, protein and cell wall synthesis.

# Predicted_LogP_Hydrophobicity:
0.03

# Predicted_LogS:
-2.8

# Predicted_Water_Solubility:
4.15e-01 g/l

# Primary_Accession_No:
DB00698

# Protein_Binding:
20-60% bound to plasma proteins

# PubChem_Compound_ID:
5353830

# PubChem_Substance_ID:
46504447

# RxList_Link:
http://www.rxlist.com/cgi/generic/nitro25m.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00191

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[O-][N+](=O)C1=CC=C(O1)\C=N/N1CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Acute toxicity may cause vomiting. Adverse effects include nausea and urine discolouration. Rare hepatotoxic and hypersensitivity reactions have occurred. Hemolytic anemia is a risk in patients with G6PD deficiency. Ascending polyneuropathy may occur with prolonged therapy or in patients with low creatinine clearance.

# Update_Date:
2013-02-08 16:19:34 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitrofurantoin

# pKa_Isoelectric_Point:
7.2

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
POR

# Phase_1_Metabolizing_Enzyme_1_ID:
4120

# Phase_1_Metabolizing_Enzyme_1_Name:
NADPH--cytochrome P450 reductase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>NADPH--cytochrome P450 reductase
MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTL
TSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLA
DLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEH
FNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEES
SIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHL
MHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHP
FPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWV
VEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYET
KAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPF
IGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQS
HKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVD
YIKKLMTKGRYSLDVWS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P16435

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12069963	Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, Hoffman PS: Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002 Jul;46(7):2116-23.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6363380	Breeze AS, Obaseiki-Ebor EE: Nitrofuran reductase activity in nitrofurantoin-resistant strains of Escherichia coli K12: some with chromosomally determined resistance and others carrying R-plasmids. J Antimicrob Chemother. 1983 Dec;12(6):543-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U00096

# Drug_Target_1_GenBank_ID_Protein:
1787642

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ydbK

# Drug_Target_1_Gene_Sequence:
>3525 bp
TTAATCGGTGTTGCTTTTTTCCGCTTTTCCGGCCATTTGTGCCAGGAAGTCATAGCGTTT
TTGCAAATCAGCTGCAGCATCTTTCCATAACTGTTCTGCCACTTCTGGCTGCTGCGAATT
CAGCCGACGGAAACGTTGCTCGTGAAGTAACGTTTCTTCCGGTGCTTCTGACGGCGGGCG
TGAATCCAAGGCCAGCGGCAGTTTGCCTTCATCGGCACGACGCGGATCAAAGCGATATAG
CGGCCAGAAGCCGGTAGCTGTGAGTTGGCGCATCTGGTCGTGGCTGAGTGCCAGATCGTA
ACCATGCTCTTCACACGGGCTATAAGCAATGATCAGCGATGGCCCCGGATACGCTTCCGC
TTCCTGAATCGCTTTCACCGTCTGGTTCAGCTGCGCGCCGAGAGAAATCTGCGCCACATA
AACATGACCGTACATCATCATACTGACGCCAAGATCTTTACGCGCTTTACGTTTGCCGTG
CTCGCCAAATTTAGTTACTGCACCCAGCGGTGTCGCTTTCGACGCCTGACCACCGGTGTT
GGAATAGCATTGCGTATCCAGCACCAGAATGTTGACGTTTTCCGTCAAACTCAATACATG
ATCCAGACCGCCAAAGCCGATATCGTAAGCCCAGCCATCACCACCAATCAGCCAGATTGA
TTTTTCCACCAGTGCATCTGCATCACGTAGCAGTTCATGTGCTTCGGCAACATCGTTGAG
TTGCTGGCGTAAAGCTGCAACCTGTTCACGACGAACCTCTGGCGTGGCGTCTGATTTCAA
CGCCGTCAGTAATTCCGCCGGGATTTTATCGGCAAATTGATCCAGCAGACGCAGCACGCG
GACACGGTGTTGATCGACCGTCAGGCGGAAACCAAGGCCAAATTCGGCATTATCTTCAAA
TAGAGAGTTCGCCCATGCCGGCCCACGACCGTTGGCATCGGTGGTATACGGTGTAGAGGG
CAGGTTACCGCCATAAATTGAAGAACAGCCAGTGGCGTTAGCGATCAACATCCGGTCGCC
ATAGAGCTGAGTCAGTAATTTAATATACGGCGTCTCGCCACAACCGGAGCAAGCACCTGA
ATATTCAAACAGCGGTGTAATCAGCTGCGATGTACGAATATCAATACGTTCCAGTTTGCT
ACGGTCGATTTCTGGCAGGTTGAGGAAGAAATCGTAATTGATTTTCTCTTCTTCGACATG
TTCCAGGCGAGACATCATATTGATGGCTTTAATCTCTGGATTCTGACGGTCTTTCGCCGG
GCAAACTTCGACGCACAGGTTACAACCGGTGCAATCTTCCGGTGCCACCTGCAAGACATA
TTTCTGCCCGCGCATATCACGCGATTTCACATCCAGCGAATGCAGGCTGGCAGGGGCGTT
TTCCATCGCTTCAGGCGGCACCACTTTTGCGCGAATAGCTGAGTGTGGGCAAGCGGCAAC
GCAGTGGTTACATTGGGTACAGAGTTCCTCTTTCCAGATGGGGATCTCTTCGGCGATATT
GCGTTTTTCCCAGCGCGTAGTGCCCATCGGCCAGGTGCCGTCTGGCGGCAGCGCCGAAAC
GGGGAGGGCGTCACCAAGCCCGGCGAGCATCGCAGCGGTTACGGTTTTCACGAAATCAGG
GGCGGCATCGGAAACCACTGGCGGTCGATTGGCGCTGTGCGGATTTACCGGTTGCAACGG
AACTTCTTCTACGGATTCACGCGCCAGCGCCAGAGCCTGCCAGTTGCGTTCCACCAGATC
CTGGCCTTTGCTACTGTAACTTTTGGCAATCGCACCCTGCAATTCTGCGAGGGCGCTATC
GCCAGGCAGAATTTGCGTCAGATGGAAAAAAGCCATCTGCATGACGGTATTAATACGGGC
CGCCAGGCCACATTCGCGGGCGATTTTCGCCGCGTTAATCACATAGAAGCGCGCTTTTTT
CTGGTTTAACACGGCCTGAACTTCTTGCGGCAAGCGCGACCACACTTCATCTGCGCTGTA
CGGCGTGTTGAGCAGGAAAATGCCGCCAGGTTTTAAACGCTCAGCCATCTGATATTTATC
GATAAACTGCAACTGGTGGCAGCCAACAAAATCAGCCTGGGAAATGAGATAAGCGGAACG
AATCGGCTGTTCGCTCACTCGAAGGTGAGAAACCGTCAGGCCGCCCGCCTTTTTGGAGTC
GTAAACAAAATAGCCCTGTGCGTACCACGGCGTGGAATTACCGATAATCTTGATATTGTT
TTTGGTCGCGGAAACGCTGCCATCACTACCAAGGCCATAAAACAAGGCTTCCAGTTTCGC
CGAGTTTGGCAGGGTGTTTTCCGGCAACGGCAGTGACAGATTGGTCACATCATCGTAAAT
ACCAACCGTAAAGCGCGCTTTCGGTTTAGCCGCGTTGAGCTCGGCAAATACCGCCAGTAC
ACAGTCTGGGCCAAATTCTTTGGATGAAAGACCATAGCGCCCACCAATGACACGGGGCAG
AGTTTCGCGCTCGCCATTATTAAAGGCTTCTGCCAGTGCGGTCATTACATCCAGATAGAG
CGGTTCTGCCTGGGCACCGGGTTCTTTGGTTCTGTCCAGTACCGCCACGCTGCGTACGGA
TCCCGGCAGAGCTTGCAGTAAATGTTTAGCGGAGAAGGGGCGGTACAGGCGAACTTTCAG
CACGCCAACTTTTTCGCCACGGGTTAGCAATTCATCAACCACTTCTTCACAGGTGCCAAT
GGCAGAGCCCATCAGGATAATCACCCGTTCCGCTTGCGGATGCCCGTAATATTCAAACGG
CTGATACTGACGACCTGTCGCGGCAGAGAAATCATTCATCGCCTGTTCAACATGGTCATA
GACCGCGTTGTACCATGGGTTGGTGGCTTCGCGAGACTGGAAATAAGTGTCAGGATTGGC
GGACGTACCGCGGATCACCGGATGTTCCGGGTTGAGTGCCCGGGCGCGATGAGCATCAAT
TTCGACCTGCGGCATGAGATCAAGAATCGTGTCATCGGCCAGCGGGACAATTTTATTGAT
TTCGTGGGACGTGCGGAAACCATCAAAGAAATGAATAAATGGCACGCGGCTTTTCAGCGT
CGCGATTTGCGAAATGAGAGCAAAGTCTTGCGCTTCCTGGACGTTTGCTGCACACAACAT
CGCGCAACCCGTCTGGCGCACCGCCATAACGTCGGAATGATCGCCAAAAATAGAGAGTGC
ATGTGTGGCAACGGTACGTGCCGCTACATGCAGGACAAACGGTGTTAGTTCGCCTGCCAG
TTTGTACAGCGTCGGGATCATCAGCAGCAAACCCTGCGATGACGTAAACGATGTTGAAAG
GGCACCCGTCTGCAAAGCGCCATGCACGGTAGCGATAGCACCCGCTTCCGACTGCATTTC
AACCACGCGTGGTGTGTCTCCCCAAACGTTCTTTAAGCCGTTTCCGGCCCAGGCATCAGC
CTGTTCTGCCATCGTGGAACTGGGGGTAATAGGGTAGATGGCGATAACTTCACTGGTGCG
AAATGCGACCGAAGCAACCGCGCCATTACCGTCAATAGTAATCAT

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
9025293	Bunch PK, Mat-Jan F, Lee N, Clark DP: The ldhA gene encoding the fermentative lactate dehydrogenase of Escherichia coli. Microbiology. 1997 Jan;143 ( Pt 1):187-95.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4117

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
128826

# Drug_Target_1_Name:
Probable pyruvate-flavodoxin oxidoreductase

# Drug_Target_1_Number_of_Residues:
1174

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00037	Fer4
PF01558	POR
PF01855	POR_N
PF02775	TPP_enzyme_C

# Drug_Target_1_Protein_Sequence:
>Probable pyruvate-flavodoxin oxidoreductase
MITIDGNGAVASVAFRTSEVIAIYPITPSSTMAEQADAWAGNGLKNVWGDTPRVVEMQSE
AGAIATVHGALQTGALSTSFTSSQGLLLMIPTLYKLAGELTPFVLHVAARTVATHALSIF
GDHSDVMAVRQTGCAMLCAANVQEAQDFALISQIATLKSRVPFIHFFDGFRTSHEINKIV
PLADDTILDLMPQVEIDAHRARALNPEHPVIRGTSANPDTYFQSREATNPWYNAVYDHVE
QAMNDFSAATGRQYQPFEYYGHPQAERVIILMGSAIGTCEEVVDELLTRGEKVGVLKVRL
YRPFSAKHLLQALPGSVRSVAVLDRTKEPGAQAEPLYLDVMTALAEAFNNGERETLPRVI
GGRYGLSSKEFGPDCVLAVFAELNAAKPKARFTVGIYDDVTNLSLPLPENTLPNSAKLEA
LFYGLGSDGSVSATKNNIKIIGNSTPWYAQGYFVYDSKKAGGLTVSHLRVSEQPIRSAYL
ISQADFVGCHQLQFIDKYQMAERLKPGGIFLLNTPYSADEVWSRLPQEVQAVLNQKKARF
YVINAAKIARECGLAARINTVMQMAFFHLTQILPGDSALAELQGAIAKSYSSKGQDLVER
NWQALALARESVEEVPLQPVNPHSANRPPVVSDAAPDFVKTVTAAMLAGLGDALPVSALP
PDGTWPMGTTRWEKRNIAEEIPIWKEELCTQCNHCVAACPHSAIRAKVVPPEAMENAPAS
LHSLDVKSRDMRGQKYVLQVAPEDCTGCNLCVEVCPAKDRQNPEIKAINMMSRLEHVEEE
KINYDFFLNLPEIDRSKLERIDIRTSQLITPLFEYSGACSGCGETPYIKLLTQLYGDRML
IANATGCSSIYGGNLPSTPYTTDANGRGPAWANSLFEDNAEFGLGFRLTVDQHRVRVLRL
LDQFADKIPAELLTALKSDATPEVRREQVAALRQQLNDVAEAHELLRDADALVEKSIWLI
GGDGWAYDIGFGGLDHVLSLTENVNILVLDTQCYSNTGGQASKATPLGAVTKFGEHGKRK
ARKDLGVSMMMYGHVYVAQISLGAQLNQTVKAIQEAEAYPGPSLIIAYSPCEEHGYDLAL
SHDQMRQLTATGFWPLYRFDPRRADEGKLPLALDSRPPSEAPEETLLHEQRFRRLNSQQP
EVAEQLWKDAAADLQKRYDFLAQMAGKAEKSNTD

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Oxidoreductase required for the transfer of electrons from pyruvate to flavodoxin (Potential)

# Drug_Target_1_SwissProt_ID:
P52647

# Drug_Target_1_SwissProt_Name:
NIFJ_ECOLI

# Drug_Target_1_Synonyms:
EC 1.2.7.-

# Drug_Target_1_Theoretical_pI:
5.57

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10832075	Lightfoot RT, Shuman D, Ischiropoulos H: Oxygen-insensitive nitroreductases of Escherichia coli do not reduce 3-nitrotyrosine. Free Radic Biol Med. 2000 Apr 1;28(7):1132-6.
16187099	Kutty R, Bennett GN: Biochemical characterization of trinitrotoluene transforming oxygen-insensitive nitroreductases from Clostridium acetobutylicum ATCC 824. Arch Microbiol. 2005 Nov;184(3):158-67. Epub 2005 Nov 10.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U18655

# Drug_Target_2_GenBank_ID_Protein:
609324

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
nfsA

# Drug_Target_2_Gene_Sequence:
>723 bp
ATGACGCCAACCATTGAACTTATTTGTGGCCATCGCTCCATTCGCCATTTCACTGATGAA
CCCATTTCCGAAGCGCAGCGTGAGGCGATTATTAACAGCGCCCGTGCGACGTCCAGTTCC
AGTTTTTTGCAGTGCAGTAGCATTATTCGCATTACCGACAAAGCGTTACGTGAAGAACTG
GTGACGCTGACCGGCGGGCAAAAACACGTAGCGCAAGCGGCGGAGTTCTGGGTGTTCTGT
GCCGACTTTAACCGCCATTTACAGATCTGTCCGGATGCTCAGCTCGGCCTGGCGGAACAA
CTGTTGCTCGGTGTCGTTGATACGGCAATGATGGCGCAGAATGCATTAATCGCAGCGGAA
TCGCTGGGATTGGGCGGGGTATATATCGGCGGCCTGCGCAATAATATTGAAGCGGTGACG
AAACTGCTTAAATTACCGCAGCATGTTCTGCCGCTGTTTGGGCTGTGCCTTGGCTGGCCT
GCGGATAATCCGGATCTTAAGCCGCGTTTACCGGCCTCCATTTTGGTGCATGAAAACAGC
TATCAACCGCTGGATAAAGGCGCACTGGCGCAGTATGACGAGCAACTGGCGGAATATTAC
CTCACCCGTGGCAGCAATAATCGCCGGGATACCTGGAGCGATCATATCCGCCGAACAATC
ATTAAAGAAAGCCGCCCATTTATTCTGGATTATTTGCACAAACAGGGTTGGGCGACGCGC
TAA

# Drug_Target_2_General_Function:
Energy production and conversion

# Drug_Target_2_General_References:
11034992	Kobori T, Sasaki H, Lee WC, Zenno S, Saigo K, Murphy ME, Tanokura M: Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitrocompounds: alteration of pyridine nucleotide binding by a single amino acid substitution. J Biol Chem. 2001 Jan 26;276(4):2816-23. Epub 2000 Oct 16.
2570347	Kang WK, Icho T, Isono S, Kitakawa M, Isono K: Characterization of the gene rimK responsible for the addition of glutamic acid residues to the C-terminus of ribosomal protein S6 in Escherichia coli K12. Mol Gen Genet. 1989 Jun;217(2-3):281-8.
7568050	Chatterjee PK, Sternberg NL: A general genetic approach in Escherichia coli for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8950-4.
8755878	Zenno S, Koike H, Kumar AN, Jayaraman R, Tanokura M, Saigo K: Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9440535	Zenno S, Kobori T, Tanokura M, Saigo K: Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
685

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
26801

# Drug_Target_2_Name:
Oxygen-insensitive NADPH nitroreductase

# Drug_Target_2_Number_of_Residues:
240

# Drug_Target_2_PDB_ID:
1F5V

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00881	Nitroreductase

# Drug_Target_2_Protein_Sequence:
>Oxygen-insensitive NADPH nitroreductase
MTPTIELICGHRSIRHFTDEPISEAQREAIINSARATSSSSFLQCSSIIRITDKALREEL
VTLTGGQKHVAQAAEFWVFCADFNRHLQICPDAQLGLAEQLLLGVVDTAMMAQNALIAAE
SLGLGGVYIGGLRNNIEAVTKLLKLPQHVLPLFGLCLGWPADNPDLKPRLPASILVHENS
YQPLDKGALAQYDEQLAEYYLTRGSNNRRDTWSDHIRRTIIKESRPFILDYLHKQGWATR

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Reduction of nitroaromatic compounds using NADH. Reduces nitrofurazone by a ping-pong bi-bi mechanism possibly to generate a two-electron transfer product. Major component of the oxygen- insensitive nitroreductase activity in E.coli

# Drug_Target_2_SwissProt_ID:
P17117

# Drug_Target_2_SwissProt_Name:
NFSA_ECOLI

# Drug_Target_2_Synonyms:
EC 1.-.-.-
Modulator of drug activity A

# Drug_Target_2_Theoretical_pI:
6.94

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
V00344

# Drug_Target_3_GenBank_ID_Protein:
42857

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
rpsJ

# Drug_Target_3_Gene_Sequence:
>312 bp
ATGCAGAACCAAAGAATCCGTATCCGCCTGAAAGCGTTTGATCATCGTCTGATCGATCAA
GCAACCGCGGAAATCGTCGAGACTGCCAAGCGCACTGGTGCGCAGGTCCGTGGTCCGATC
CCGCTGCCGACACGCAAAGAGCGCTTCACTGTTCTGATCTCCCCGCACGTCAACAAAGAC
GCGCGCGATCAGTACGAAATCCGTACTCACTTGCGTCTGGTTGACATCGTTGAGCCAACC
GAGAAAACCGTTGATGCTCTGATGCGTCTGGATCTGGCTGCCGGTGTAGACGTGCAGATC
AGCCTGGGTTAA

# Drug_Target_3_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_3_General_References:
10094780	Arnold RJ, Reilly JP: Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal Biochem. 1999 Apr 10;269(1):105-12.
12244297	Tung CS, Joseph S, Sanbonmatsu KY: All-atom homology model of the Escherichia coli 30S ribosomal subunit. Nat Struct Biol. 2002 Oct;9(10):750-5.
12809609	Gao H, Sengupta J, Valle M, Korostelev A, Eswar N, Stagg SM, Van Roey P, Agrawal RK, Harvey SC, Sali A, Chapman MS, Frank J: Study of the structural dynamics of the E coli 70S ribosome using real-space refinement. Cell. 2003 Jun 13;113(6):789-801.
3892488	Zurawski G, Zurawski SM: Structure of the Escherichia coli S10 ribosomal protein operon. Nucleic Acids Res. 1985 Jun 25;13(12):4521-6.
7007073	Yaguchi M, Roy C, Wittmann HG: The primary structure of protein S10 from the small ribosomal subunit of Escherichia coli. FEBS Lett. 1980 Nov 17;121(1):113-6.
7037196	Olins PO, Nomura M: Regulation of the S10 ribosomal protein operon in E. coli: nucleotide sequence at the start of the operon. Cell. 1981 Oct;26(2 Pt 2):205-11.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
176

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
11736

# Drug_Target_3_Name:
30S ribosomal protein S10

# Drug_Target_3_Number_of_Residues:
103

# Drug_Target_3_PDB_ID:
1P87

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00338	Ribosomal_S10

# Drug_Target_3_Protein_Sequence:
>30S ribosomal protein S10
MQNQRIRIRLKAFDHRLIDQATAEIVETAKRTGAQVRGPIPLPTRKERFTVLISPHVNKD
ARDQYEIRTHLRLVDIVEPTEKTVDALMRLDLAAGVDVQISLG

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Involved in the binding of tRNA to the ribosomes

# Drug_Target_3_SwissProt_ID:
P0A7R5

# Drug_Target_3_SwissProt_Name:
RS10_ECOLI

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
10.34

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00698
